This is a non-core endpoint: only basic statistics are computed.
Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)
C3_LYMPHNODES_SECONDARY_NAS_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Cause of death: ICD-10
C77
Cause of death: ICD-8
196
Cancer registry: Topography ICD-O-3
C77
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
3
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
2139
C3_LYMPHNODES_SECONDARY_NAS_EXALLC
Control definitions
Control exclude
C3_CANCER, C3_CANCER_WIDE
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Secondary and unspecified malignant neoplasm of lymph nodes
- Secondary uncertain malignant neoplasm (controls excluding all cancers)
- Secondary uncertain malignant neoplasm
- Malignant neoplasm (controls excluding all cancers)
- Malignant neoplasm
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 2139 | 932 | 1207 |
| Unadjusted prevalence (%) | 0.57 | 0.44 | 0.73 |
| Mean age at first event (years) | 56.08 | 52.91 | 58.52 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_LYMPHNODES_SECONDARY_NAS_EXALLC – Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Secondary and unspecified malignant neoplasm of lymph nodes (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.